The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of coadministration of propranolol and etodolac (VT-122) plus sorafenib for patients with advanced hepatocellular carcinoma (HCC).
 
Andrew N de la Torre
Research Funding - Vicus Therapeutics (Inst)
 
Ismael Castaneda
No Relationships to Disclose
 
Aram F. Hezel
Research Funding - Vicus Therapeutics (Inst)
 
Newell F. Bascomb
Employment - Vicus Therapeutics
Stock and Other Ownership Interests - Vicus Therapeutics
Patents, Royalties, Other Intellectual Property - Vicus Therapeutics
 
Gouri Shankar Bhattacharyya
Consulting or Advisory Role - Vicus Therapeutics
Research Funding - Vicus Therapeutics (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Astellas Pharma; AstraZeneca (I); Celgene; Celsion; cipla; Exelixis; IntegraGen; Jennerex; Lilly/ImClone; MedImmune; Novartis; Pharmacyclics (I); Sanofi (I); Silenseed (I); Vicus Therapeutics
Research Funding - Abbott Laboratories (Inst); Amgen (Inst); Bayer (Inst); Exelixis (Inst); Genentech (Inst); Lilly/ImClone (Inst); Novartis (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris